25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China (RaTAPDR)

JUNYAN ZHANG

Status and phase: Unknown; Phase 3; Phase 2

Conditions: Proliferative Diabetic Retinopathy

Treatments: Drug: Triamcinolone Acetonide; Drug: Ranibizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT02328118

PDR-RAN-LSY

Details and patient eligibility

About

Proliferative diabetic retinopathy(PDR) is the leading cause of visual loss in diabetic patients. Operation is an efficient method to treat PDR. Anti-vascular endothelial growth factor (anti-VEGF) can be used as an adjuvant therapy which can make operation more easy.

Full description

Proliferative diabetic retinopathy(PDR) is the leading cause of visual loss in diabetic patients. The operation indication includes non-absorbed vitreous haemorrhage, dense bleeding in front of the macular, proliferative vitreoretinopathy traction macular, tractional retinal detachment combined break, severe progressive fiber vascular proliferation and vitreous haemorrhage combined with early iris neovascularization.

Due to VEGF levels rise in vitreous cavity of PDR patients, some inflammatory cytokines involved in, make easy bleeding during surgery and heavier inflammatory reaction postoperation,thus affecting the curative effect of the operation.

Ranibizumab as angiogenesis inhibitors, has widely applied in the treatment of age-related macular degeneration, won the recognition of ophthalmologists.

Some scholars try to expand the application in diabetic macular edema, also obtained the good curative effect.Some scholars also applied the angiogenesis inhibitors to the diabetes retinopathy before surgery in the hope to reduce the occurrence of intraoperative bleeding.Compared with bevacizumab, the short half-life of lucentis, and thus reduce the inhibition of VEGF system risk.

In this project, the investigators will inject lucentis into vitreous cavity before surgery of PDR, and observe the effect and complications of the operation, compared with triamcinolone acetonide group(the control group); At the same time the cytokines level of VEGF, pigment epithelium-derived factor (PEDF), epidermal growth factor (EGF), Transforming Growth Factor-beta (TGF-beta), interleukin 6 (IL - 6) and interleukin 8 (IL - 8) will be detected before and after pretreatment with lucentis or triamcinolone acetonide, and the cytokines concentration change will be compared between two groups, the mechanism of PDR will be further clarified and theoretical basis for looking for treatment strategies will be laid.

Enrollment: 120 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type II diabetes mellitus with Diabetic Retinopathy
• Vitreous hemorrhage/Proliferation of retinal/Tractional detachment of retina
• Fasting blood-glucose no more than 8mmol/ml

Exclusion criteria

• Subjects who have operation on vitreous before
• Accompany with other ophthalmology diseases except cataract
• History of vitrectomy surgery in the study eye
• Previous subfoveal focal laser photocoagulation in the study eye
• Previous participation in a clinical trial (for either eye)
• Previous subfoveal focal laser photocoagulation in the study eye
• Other diseases cannot afford Vitrectomy

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

120 participants in 2 patient groups

Ranibizumab 0.5 mg

Experimental group

Description:

All subjects in this group will receive Ranibizumab (0.5mg/0.05ml) intravitreal injection.

Treatment:

Drug: Ranibizumab

Drug: Triamcinolone Acetonide

Triamcinolone Acetonide 4mg

Experimental group

Description:

All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.

Treatment:

Drug: Triamcinolone Acetonide